Amylyx Pharmaceuticals (AMLX) Accumulated Depreciation & Amortization (2021 - 2024)
Historic Accumulated Depreciation & Amortization for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q4 2024 value amounting to $1.4 million.
- Amylyx Pharmaceuticals' Accumulated Depreciation & Amortization fell 1652.33% to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.4 million, marking a year-over-year decrease of 1652.33%. This contributed to the annual value of $1.4 million for FY2024, which is 1652.33% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Accumulated Depreciation & Amortization of $1.4 million as of Q4 2024, which was down 1652.33% from $1.6 million recorded in Q4 2023.
- In the past 5 years, Amylyx Pharmaceuticals' Accumulated Depreciation & Amortization registered a high of $1.6 million during Q4 2023, and its lowest value of $53000.0 during Q4 2021.
- Its 4-year average for Accumulated Depreciation & Amortization is $895000.0, with a median of $949500.0 in 2022.
- As far as peak fluctuations go, Amylyx Pharmaceuticals' Accumulated Depreciation & Amortization soared by 91886.79% in 2022, and later crashed by 1652.33% in 2024.
- Over the past 4 years, Amylyx Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $53000.0 in 2021, then surged by 918.87% to $540000.0 in 2022, then soared by 201.48% to $1.6 million in 2023, then fell by 16.52% to $1.4 million in 2024.
- Its Accumulated Depreciation & Amortization was $1.4 million in Q4 2024, compared to $1.6 million in Q4 2023 and $540000.0 in Q4 2022.